SF1126

DRUG4 trials

Sponsors

Semafore Pharmaceuticals, New Approaches to Neuroblastoma Therapy Consortium, Ezra Cohen, SignalRX Pharmaceuticals, Inc.

Conditions

Advanced Hepatocellular CarcinomaAdvanced or Metastatic Solid TumorsCancerMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaNeuroblastomaSolid Cancers

Phase 1

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

CompletedNCT00907205

Semafore PharmaceuticalsAdvanced or Metastatic Solid Tumors, Cancer, Solid Cancers

Start: 2007-04-30End: 2011-04-30Updated: 2013-06-13

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

TerminatedNCT02337309

New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma

Start: 2015-07-09End: 2018-05-22Updated: 2018-08-20

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma

TerminatedNCT03059147

SignalRX Pharmaceuticals, Inc.Advanced Hepatocellular Carcinoma

Start: 2017-03-27End: 2020-06-29Updated: 2022-05-18

Phase 2

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

TerminatedNCT02644122

Ezra CohenMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

Start: 2016-11-30End: 2016-12-31Updated: 2018-07-11